Comparative Effectiveness of Risankizumab Versus Tumour Necrosis Factor Inhibitors or Interleukin-17 Inhibitors on Joint Outcomes in Biologic-Naïve Patients With Psoriatic Arthritis: A Global Real-World Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2614; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "In the overall biologic-naïve population, adalimumab was the most commonly used TNFi (62%), while secukinumab was the most used IL-17i (47%). In this real-world study, biologic-naïve patients with PsA who initiated RZB had comparable joint improvement versus those who initiated a TNFi or an IL-17i. Results demonstrate that RZB may provide similar effectiveness on joint involvement as TNFi or IL-17i in biologic-naïve patients with PsA."
Clinical • HEOR • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A
|
|
Philip Mease1; Jessica Walsh2; Xiaolan Ye3; Christopher Saffore4; Dolly Sharma4; Molly Edwards5; Isabel Truman5; Gary Milligan5; Jamie Vora4; Thomas Iyile6; Andrew Ostor7
|